Impact of young age at diagnosis on survival outcomes in patients with early breast cancer according to tumor subtype: Pooled analysis of 5 randomized clinical trials from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM)

被引：0
|
作者：
Perachino, Marta
Blondeaux, Eva
De Laurentiis, Michelino
Arpino, Grazia
Puglisi, Fabio
Fabi, Alessandra
Gori, Stefania
Poggio, Francesca
Arecco, Luca
Favero, Diletta
Sydes, Matthew R.
Lambertini, Matteo
Del Mastro, Lucia
机构：
[1] Univ Genoa, Sch Med, Dept Internal Med & Med Sci DiMI, Genoa, Italy
[2] Clin Epidemiol Unit, IRCCS Osped Policlin San Martino, Genoa, Italy
[3] Ist Nazl Tumori Napoli, IRCCS Fdn Pascale, Naples, Italy
[4] Univ Federico II, Dept Clin Med & Surg, Naples, Italy
[5] Univ Udine, Dept Med DAME, Udine, Italy
[6] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Udine, Italy
[7] IRCCS, Precis Med Unit, Senol Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[8] IRCCS Sacro Cuore Don Calabria, Calabria, Negrar Di Valpo, Italy
[9] IRCCS Osped Policlin San Martino, Dept Clin Oncol, Genoa, Italy
[10] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DIMI, Genoa, Italy
[11] HUB, Acad Trials Promoting Team, Inst Jules Bordet, Brussels, Belgium
[12] IRCCS Azienda Osped Univ San Martino, Genoa, Italy
[13] UCL, Med Res Council, London, England
[14] IRCCS Osped Policlin San Martino, Dept Med Oncol, UOC Clin Oncol Med, Genoa, Italy
[15] IRCCS Osped Policlin San Martino Genoa, Dept Clin Oncol, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
523
引用
收藏
页数：1
相关论文
共 21 条
  • [1] Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo trials (MIG)
    Blondeaux, E.
    Xie, W.
    Carmisciano, L.
    Mura, S.
    Sanna, V.
    De Laurentiis, M.
    Caputo, R.
    Turletti, A.
    Durando, A.
    De Angelis, C.
    Bisagni, G.
    Gasparini, E.
    Rimanti, A.
    Puglisi, F.
    Landucci, E.
    Fabi, A.
    Boni, L.
    Lambertini, M.
    Del Mastro, L.
    Regan, M. M.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 10 - 10
  • [2] Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials
    Blondeaux, Eva
    Xie, Wanling
    Carmisciano, Luca
    Mura, Silvia
    Sanna, Valeria
    De Laurentiis, Michelino
    Caputo, Roberta
    Turletti, Anna
    Durando, Antonio
    De Placido, Sabino
    De Angelis, Carmine
    Bisagni, Giancarlo
    Gasparini, Elisa
    Rimanti, Anita
    Puglisi, Fabio
    Mansutti, Mauro
    Landucci, Elisabetta
    Fabi, Alessandra
    Arecco, Luca
    Perachino, Marta
    Bruzzone, Marco
    Boni, Luca
    Lambertini, Matteo
    Del Mastro, Lucia
    Regan, Meredith M.
    ECLINICALMEDICINE, 2024, 70
  • [3] Dissecting the prognostic role of baseline body mass index (BMI) in early breast cancer (BC): Individual patient-level analysis from five mammella interGruppo (MIG) and gruppo italiano mammella (GIM) randomized clinical trials (RCTs)
    Soldato, Davide
    Blondeaux, Eva
    Bruzzone, Marco
    Mura, Silvia
    De laurentiis, Michelino
    Turletti, Anna
    De Placido, Sabino
    Bisagni, Giancarlo
    Rimanti, Anita
    Michelotti, Andrea
    Fabi, Alessandra
    Russo, Antonio
    Gori, Stefania
    Durando, Antonio
    Marta, Guilherme Nader
    de Azambuja, Evandro
    Di Meglio, Antonio
    Vaz-Luis, Ines
    Lambertini, Matteo
    Del Mastro, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
    Lambertini, Matteo
    Blondeaux, Eva
    Bisagni, Giancarlo
    Mura, Silvia
    De Placido, Sabino
    De Laurentiis, Michelino
    Fabi, Alessandra
    Rimanti, Anita
    Michelotti, Andrea
    Mansutti, Mauro
    Russo, Antonio
    Montemurro, Filippo
    Frassoldati, Antonio
    Durando, Antonio
    Gori, Stefania
    Turletti, Anna
    Tamberi, Stefano
    Urracci, Ylenia
    Fregatti, Piero
    Razeti, Maria Grazia
    Caputo, Roberta
    De Angelis, Carmine
    Sanna, Valeria
    Gasparini, Elisa
    Agostinetto, Elisa
    de Azambuja, Evandro
    Poggio, Francesca
    Boni, Luca
    Del Mastro, Lucia
    ECLINICALMEDICINE, 2023, 59
  • [5] Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
    Arecco, L.
    Blondeaux, E.
    Bruzzone, M.
    Arpino, G.
    De Angelis, C.
    De Laurentiis, M.
    Caputo, R.
    Fabi, A.
    Sanna, V.
    Gori, S.
    Puglisi, F.
    Boni, L.
    Nardin, S.
    Giannubilo, I.
    Perachino, M.
    Borea, R.
    Agostinetto, E.
    de Azambuja, E.
    Lambertini, M.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S316 - S316
  • [6] Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes
    Cerbone, L.
    Blondeaux, E.
    Boni, L.
    Ruelle, T.
    Russo, S.
    Bonotto, M.
    Targato, G.
    De laurentiis, M.
    Piezzo, M.
    Arpino, G.
    Pugliese, P.
    Fabi, A.
    D'Alonzo, A.
    Giannubilo, I.
    Conte, B.
    Mulinelli, C.
    Lambertini, M.
    Bighin, C.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S475 - S476
  • [7] Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella GIM)
    Del Mastro, L.
    Poggio, F.
    Blondeaux, E.
    de Placido, S.
    Giuliano, M.
    De laurentiis, M.
    Bisagni, G.
    Cantore, M.
    Turletti, A.
    Nistico, C.
    Urracci, Y.
    Garrone, O.
    Bighin, C.
    Mansutti, M.
    Montemurro, F.
    Colantuoni, G.
    Lambertini, M.
    Boni, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S599 - S600
  • [8] Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group
    Del Mastro, L.
    Costantini, M.
    Durando, A.
    Michelotti, A.
    Danese, S.
    Aitini, E.
    Olmeo, N.
    Pronzato, P.
    Venturini, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials
    Lipsyc-Sharf, Marla
    Ballman, Karla V.
    Campbell, Jordan D.
    Muss, Hyman B.
    Perez, Edith A.
    Shulman, Lawrence N.
    Carey, Lisa A.
    Partridge, Ann H.
    Warner, Erica T.
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
    van der Hage, Jos A.
    Mieog, J. Sven D.
    van de Velde, Cornelis J. H.
    Putter, Hein
    Bartelink, Harry
    van de Vijver, Marc J.
    BREAST CANCER RESEARCH, 2011, 13 (03):
123